表紙:在宅診断検査市場と動向(COVID-19、FOB、グルコース、HIV、その他検査):2023年
市場調査レポート
商品コード
1287796

在宅診断検査市場と動向(COVID-19、FOB、グルコース、HIV、その他検査):2023年

At-Home Diagnostic Testing Markets and Trends (COVID-19, FOB, Glucose, HIV and Other Tests), 2023

出版日: | 発行: Kalorama Information | ページ情報: 英文 142 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
在宅診断検査市場と動向(COVID-19、FOB、グルコース、HIV、その他検査):2023年
出版日: 2023年06月08日
発行: Kalorama Information
ページ情報: 英文 142 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、さまざまな在宅体外診断検査と在宅検体採取検査の両方を調査しています。在宅体外診断 (IVD) 検査市場は、地元の店舗またはインターネットで購入できる IVD 検査で構成されており、患者が検体を採取すると、通常は数分以内に結果が表示されます。一般に、これらはラテラルフロー技術またはディップスティック方式です。

一方、世界の在宅IVD検査市場は、多くの可能性を秘めた成長市場です。在宅検体採取 IVD 検査市場は、地元の薬局またはインターネットから入手して患者の自宅に送付される検査キットで構成されています。患者は検体を採取し、採取容器に入れて検査のために検査室に送ります。結果は患者および/または紹介医師に返送されます。

このレポートは、在宅および自宅検査市場を次のようないくつかの広範な領域に分類してカバーしています。

  • コレステロール
  • 乱用薬物
  • 便潜血
  • グルコース/HbA1c(CGMを含む)
  • 感染症
    • COVID-19/ + インフルエンザ + RSウイルス
    • HIV
  • 妊娠と生殖能力
  • 急速凝固
  • 遺伝的(祖先遺伝子検査を除く)

レポートで取り上げられるデータの基準年は 2022 年です。データは 2022 年と 2027 年の複合年間成長率 (CAGR) とともに提供されます。競合分析は市場の上位 5 社の参加者に対して提供されます。地域の内訳は、2019 年から 2022 年にかけて、米国、EMEA、アジア太平洋、および世界のその他の国について調査されています。 2022 年から 2027 年の予測市場分析は主に、人口動態の動向、新開発、革新的な技術、世界の拡大に基づいています。

当レポートでは、在宅診断検査市場について調査し、在宅検査の概要と、セグメント別動向、市場参入企業、および競合分析などをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 イントロダクション

  • 概要
  • 課題と動向
  • COVID-19
  • 在宅検査のための保険
  • 在宅IVD検査の促進要因と課題
  • 遺伝学
  • 在宅検体採取

第3章 在宅IVD検査

  • イントロダクション
  • 糖尿病
  • 妊娠・不妊
  • 感染症
  • HIV
  • COVID-19
  • COVID-19とインフルエンザ
  • 凝固
  • 便潜血
  • コレステロール
  • 乱用薬物
  • 在宅IVD検査市場、検査タイプ別
  • 在宅IVD検査市場、サンプルタイプ別
  • 血液サンプル
  • 尿サンプル
  • 口腔/唾液サンプル
  • 鼻サンプル
  • 便サンプル
  • その他

第4章 在宅検体採取IVD検査

  • イントロダクション
  • 妊娠と生殖能力
  • 感染症
  • HIV
  • HPVおよびその他の性感染症
  • COVID-19
  • COVID-19とインフルエンザ
  • 便潜血
  • コレステロール
  • 遺伝学
  • 在宅検体採取IVD検査、検査タイプ別
  • プライバシー
  • 在宅検体採取IVD検査、サンプルタイプ別
  • 血液サンプル
  • 尿サンプル
  • 口腔/唾液サンプル
  • 鼻サンプル
  • 便サンプル
  • その他

第5章 市場参入企業

  • 23andMe, Inc.
  • Abbott Diagnostics
  • AccessBio, Inc
  • ARKRAY, Inc.
  • Ascensia Diabetes Care Holdings AG
  • Atomo Diagnostics
  • Becton-Dickinson
  • binx health
  • Biomerica, Inc
  • Biosynex SA
  • BTNX Inc.
  • Church & Dwight Co. Inc.
  • Color Health, Inc.
  • Cue Health
  • Dexcom, Inc.
  • EasyDNA
  • Everlywell
  • Exact Sciences
  • First Check Diagnostics LLC
  • GlysBy diagnostics
  • Helena Laboratories
  • Hemosure, Inc.
  • LifeScan, Inc.
  • Medichecks.com Ltd
  • Myriad Genetics, Inc.
  • OraSure Technologies, Inc.
  • Polymedco, Inc.
  • Preventis GmbH
  • Prima Lab SA
  • QuidelOrtho Corporation
  • Roche Diagnostic Corporation
  • Siemens Healthineers GmbH
  • Swiss Precision Diagnostics GmbH
  • Trividia Health
  • VedaLab

第6章 市場分析

  • 市場概要
  • 検査タイプ別市場セグメント
  • グルコースとHbA1c
  • 感染症
  • その他の分野
  • 遺伝的
  • 流通別市場
  • 地域別市場
  • 競合分析
目次
Product Code: 23-720c

This new Kalorama Information report, “At-Home Diagnostic Testing Markets and Trends (COVID-19, FOB, Glucose, HIV and Other Tests), 2023”, examines a range of both at-home tests and home collection tests. The At-Home in vitro diagnostic (IVD) testing market is comprised of IVD tests that can be purchased at the local store or on the Internet where the patient gathers the specimen and results are displayed usually within minutes. Generally, these are lateral flow technology or dip stick methods.

Meanwhile, the global Home IVD testing market is a growing market with much potential. The Home Collection IVD testing market is comprised of testing kits that are obtained from the local pharmacy or internet and sent to the patient's home. The patient collects the specimen, puts it into a collection container and sends it to the laboratory for testing. Results are sent back to the patient and/or referring physician.

This report covers the At-Home and Home testing markets by segmenting them into several broad areas including:

  • Cholesterol
  • Drugs of Abuse
  • Fecal Occult Blood
  • Glucose/ HbA1c including CGM
  • Infectious Disease
    • COVID-19 / + Flu + RSV
    • HIV
  • Pregnancy and Fertility
  • Rapid Coagulation
  • Genetic (excluding ancestry genetic testing)

The base year for data featured in the report is 2022. Data are provided for 2022 and 2027 with compound annual growth rates (CAGRs) for 2022 and 2027. Competitive analysis is provided for the top five participants in the market. Regional breakdowns are surveyed for United States, EMEA, Asia-Pacific and Rest of World for 2019-2022. The forecasted market analysis for 2022-2027 was largely based on demographic trends, new developments, innovative technology and global expansion.

Table of Contents

Chapter 1: Executive Summary

  • Industry at a Glance
  • Scope and Methodology
  • Size and Growth of the Market
    • Figure 1-1: Global Home IVD Market, by Key Segment (Glucose/HbA1c, COVID-19, Other, Genetic), 2019-2022
  • Key Issues and Trends Affecting the Market
  • Competitive Outlook
  • Conclusion Highlights

Chapter 2: Introduction

  • Overview
  • Issues and Trends
  • COVID-19
    • Figure 2-1: Home COVID-19 Test Distribution of Sales by Vendor (Abbott Diagnostics, Becton Dickinson, OraSure Technologies, Siemens Healthineers, Quidel, Others)
  • Insurance for Home Tests
    • Figure 2-2: Diabetes State Mandates - State-Level Insurance Mandates for Benefits, ACA Marketplace Coverage
  • Home IVD Testing Drivers and Challenges
    • Figure 2-3: Benefits to Home Testing vs. Challenges in Home Testing
  • Genetics
    • Table 2-1: Home Genetic Laboratory Testing, Market Drivers and Barriers
  • Home Collection

Chapter 3: At-Home IVD Tests

  • Introduction
  • Diabetes
    • Table 3-1: Selected Glucose At-Home Testing Meter Innovations
  • Pregnancy and Fertility
  • Infectious Disease
  • HIV
  • COVID-19
  • COVID-19 & Flu
    • Table 3-2: Selected COVID- 19 and COVID-19 & Flu A/B At-Home Tests for SARS-CoV-2
  • Coagulation
  • Fecal Occult Blood
  • Cholesterol
  • Drugs of Abuse
  • At-Home IVD Test Market by Test Type
    • Table 3-3: Global At-Home IVD Market by Test Type (Glucose, Infectious Disease, Other), 2022 ($BN)
    • Figure 3-1: Global At-Home IVD Market by Distribution of Sales by Segment (Glucose, COVID-19+, HIV, Other Infections, Cholesterol, Drug of Abuse, Coagulation, FOB, Pregnancy & Fertility, Other), 2022
  • At-Home IVD Tests Market by Sample Type
    • Table 3-4: Global At-Home IVD Market by Sample Type (Blood, Nasal, Oral/Saliva, Stool, Urine, Other), 2022 ($BN)
    • Figure 3-2: Global At-Home IVD Market by Distribution of Sales by Sample Type (Blood, Urine, Oral/Saliva, Nasal, Stool, Other), 2019 and 2022
    • Figure 3-3: Year-over-Year Growth for At-Home IVD Markets (Cholesterol, Coagulation, COVID-19, Drugs of Abuse, FOB, Glucose, HIV, Other Infections, Pregnancy & Fertility, Other), 2020-2021 and 2021-2022 (%)
  • Blood Samples
    • Figure 3-4: Estimated Distribution of Blood Sample Sales by Test Type (Cholesterol, Coagulation, Glucose, Other), 2022 (%)
  • Urine Samples
    • Figure 3-5: Estimated Distribution of Urine Sample Sales, by Test Type (Drug of Abuse, Infectious Disease, Pregnancy, Other), 2022 (%)
  • Oral/Saliva Samples
    • Figure 3-6: Estimated Distribution of Oral/Saliva Sample Sales by Test Type (COVID-19, Drug of Abuse, HIV, Other), 2022 (%)
  • Nasal Samples
    • Figure 3-7: Estimated Distribution of Nasal Sample Sales by Test Type (COVID-19, Other), 2022 (%)
  • Stool Samples
    • Figure 3-8: Estimated Distribution of Stool Sample Sales by Test Type (FOB, Other), 2022 (%)
  • Other

Chapter 4: Home Collection IVD Tests

  • Introduction
  • Pregnancy and Fertility
  • Infectious Disease
  • HIV
  • HPV and other STDs
  • COVID-19
  • COVID-19 & Flu
    • Table 4-1: Selected Molecular EUA Tests for COVID-19
  • Fecal Occult Blood
  • Cholesterol
  • Genetics
  • Home Collection IVD Tests by Test Type
    • Table 4-2: Global Home Collection IVD Market by Test Type (Genetics, Infectious Disease, Other Areas), 2022 ($BN)
    • Figure 4-1: Global Home IVD Market by Distribution of Sales by Segment (Cholesterol, Coagulation, COVID-19, Drug of Abuse, Genetic, HbA1c, HIV, Other Infections, Pregnancy & Fertility, Other), 2022 (%)
  • Privacy
  • Home Collection Tests by Sample Type
    • Table 4-3: Global Home Collection IVD Market by Sample Type (Blood, Nasal, Oral/Saliva, Stool, Urine, Other), 2022 ($BN)
    • Figure 4-2: Global Home Collection IVD Market by Distribution of Sales by Sample Type (Blood, Urine, Oral/Saliva, Nasal, Stool, Other), 2019 and 2022
    • Figure 4-3: Year-over-Year Growth for Home Collection IVD Markets, by Type (Cholesterol, Coagulation, COVID-19, Drug of Abuse, FOB, Genetic, HbA1c, HIV, Other Infections, Pregnancy & Fertility, Other), 2020-2021 and 2021-2022 (%)
  • Blood Samples
    • Figure 4-4: Estimated Distribution of Blood Sample Sales by Test Type (Cholesterol, Fertility, Genetic, Glucose/HbA1c, Infectious Disease - STD blood spot, Tumor Market - PSA blood spot, Other - hormone), 2022 (%)
  • Urine Samples
    • Figure 4-5: Estimated Distribution of Urine Sample Sales by Test Type (Infectious Disease - STD, Pregnancy/Fertility, Other - Heavy metals, hormone, nutrition), 2022 (%)
  • Oral/Saliva Samples
    • Figure 4-6: Estimated Distribution of Oral/Saliva Sample Sales by Test Type (COVID-19, Drug of Abuse, Fertility, Genetic, HIV, Other - hormone, nutrition, medication match), 2022 (%)
  • Nasal Samples
    • Figure 4-7: Estimated Distribution of Nasal Sample Sales by Test Type (COVID-19, Other), 2022 (%)
  • Stool Samples
    • Figure 4-8: Estimated Distribution of Stool Sample Sales by Test Type (FOB, Infectious Disease - pathogen ID, Other - Heavy metals), 2022 (%)
  • Other

Chapter 5: Market Participants

  • 23andMe, Inc.
    • Table 5-1: 23andMe Corporate Summary
    • Company Overview
      • Table 5-2: 23andMe Genetic Tests with FDA Marketing Authorization
    • Performance Review
      • Table 5-3: 23andMe Revenue, 2020-2022 ($ millions)
  • Abbott Diagnostics
    • Table 5-4: Corporate Summary
    • Company Overview
    • Performance Review
      • Table 5-5: Abbott Revenues, 2020-2022 (in millions $)
  • AccessBio, Inc.
    • Table 5-6: AccessBio Corporate Summary
    • Company Overview
    • ACON Laboratories, Inc.
      • Table 5-7: ACON Laboratories Corporate Summary
    • Company Overview
  • ARKRAY, Inc.
    • Table 5-8: ARKRAY Corporate Summary
    • Company Overview
  • Ascensia Diabetes Care Holdings AG
    • Table 5-9: Ascensia Diabetes Care Corporate Summary
    • Company Overview
  • Atomo Diagnostics
    • Table 5-10: Atomo Corporate Summary
    • Company Overview
    • Performance Review
      • Table 5-11: Atomo Revenues, 2021-2022 (in millions $)
  • Becton-Dickinson
    • Table 5-12: Becton-Dickinson Corporate Summary
    • Company Overview
    • Performance Review
      • Table 5-13: BD Corporation Revenue, 2020-2022 ($ millions)
  • binx health
    • Table 5-14: binx health Corporate Summary
    • Company Overview
  • Biomerica, Inc.
    • Table 5-15: Biomerica Corporate Summary
    • Company Overview
    • Company Financials
      • Table 5-16: Biomerica Corporation Revenue, 2020-2022 ($ millions)
  • Biosynex SA
    • Table 5-17: Biosynex Corporate Summary
    • Company Overview
    • Performance Review
      • Table 5-18: Biosynex Revenues 2021-2022 (in millions $)
  • BTNX Inc.
    • Table 5-19: BTNX Corporate Summary
    • Company Overview
  • Church & Dwight Co. Inc.
    • Table 5-20: Church & Dwight Corporate Summary
    • Company Overview
    • Performance Review
      • Table 5-21: Church and Dwight Revenues, 2020-2022 ($ millions)
  • Color Health, Inc.
    • Table 5-22: Color Health Corporate Summary
    • Company Overview
  • Cue Health
    • Table 5-23: Cue Health Corporate Summary
    • Company Overview
  • Dexcom, Inc.
    • Table 5-24: Dexcom Corporation Corporate Summary
    • Company Overview
    • Performance Review
      • Table 5-25: Dexcom Revenues, 2020-2022 ($ millions)
  • EasyDNA
    • Table 5-26: EasyDNA Corporate Summary
    • Company Overview
  • Everlywell
    • Table 5-27: Everlywell Corporate Summary
    • Company Overview
  • Exact Sciences
    • Table 5-28: Exact Sciences Corporate Summary
    • Company Overview
    • Performance Review
      • Table 5-29: Exact Sciences Revenues, 2020-2022 ($ millions)
  • First Check Diagnostics LLC
    • Table 5-30: First Check Diagnostics Corporate Summary
    • Company Overview
  • GlysBy diagnostics
    • Table 5-31: GlysBy Corporate Summary
    • Company Overview
  • Helena Laboratories
    • Table 5-32: Helena Laboratories Corporate Summary
    • Company Overview
  • Hemosure, Inc.
    • Table 5-33: Hemosure Corporate Summary
    • Company Overview
  • LifeScan, Inc.
    • Table 5-34: LifeScan Corporate Summary
    • Company Overview
  • Medichecks.com Ltd.
    • Table 5-35: Medichecks Corporate Summary
    • Company Overview
  • Myriad Genetics, Inc.
    • Table 5-36: Myriad Genetics Corporate Summary
    • Company Overview
    • Performance Review
      • Table 5-37: Myriad Diagnostics Revenue, 2020-2022 ($ millions)
  • OraSure Technologies, Inc.
    • Table 5-38: OraSure Technologies Summary
    • Company Overview
    • Performance Review
      • Table 5-39: OraSure Revenues, 2020-2022 ($ millions)
  • Polymedco, Inc.
    • Table 5-40: Polymedco Corporate Summary
    • Company Overview
  • Preventis GmbH
    • Table 5-41: Preventis Corporate Summary
    • Company Overview
  • Prima Lab SA
    • Table 5-42: Prima Corporate Summary
    • Company Overview
  • QuidelOrtho Corporation
    • Table 5-43: QuidelOrtho Corporate Summary
    • Company Overview
    • Performance Review
      • Table 5-44: QuidelOrtho Revenues, 2020-2022 ($ millions)
  • Roche Diagnostic Corporation
    • Table 5-45: Roche Diagnostic Corporate Summary
    • Company Overview
    • Performance Review
      • Table 5-46: Roche Diagnostics, 2020-2022 ($ millions)
  • Siemens Healthineers GmbH
    • Table 5-47: Siemens Healthineers Corporate Summary
    • Company Overview
    • Performance Review
      • Table 5-48: Siemens Healthineers, 2020-2022 ($ millions)
  • Swiss Precision Diagnostics GmbH
    • Table 5-49: Swiss Precision Diagnostics Corporate Summary
    • Company Overview
  • Trividia Health
    • Table 5-50: Trividia Health Corporate Summary
    • Company Overview
  • VedaLab
    • Table 5-51: VedaLab Corporate Summary
    • Company Overview

Chapter 6: Market Analysis

  • Market Overview
    • Figure 6-1: Global Home IVD Market, 2022-2027, 5% CAGR, ($MN)
  • Market Segment by Test Type
    • Figure 6-2: Global Home IVD Market by Test Type (Genetic, Glucose/HbA1c, Infectious Disease, Other Areas), 2019-2022 ($MN)
    • Figure 6-3: Global Home IVD Market, by General Test Segment (Genetic, Glucose/HbA1c, Infectious Disease, Other Areas), 2022
  • Glucose & HbA1c
    • Table 6-1: Estimated Global Home IVD Glucose & HbA1c Testing Market, 2022-2027 $MN; CAGR 22-27
  • Infectious Disease
    • Table 6-2: Estimated Global Home IVD Infectious Disease Testing Market, 2022-2027 $MN; CAGR 22-27
  • Other Areas
    • Table 6-3: Estimated Global Home IVD Other Testing Market, 2022-2027 $MN; CAGR 22-27
  • Genetic
    • Table 6-4: Estimated Global Home IVD Genetic Testing Market, 2022-2027 $MN; CAGR 22-27
  • Market by Distribution
  • Market by Region
    • Figure 6-4: Estimated Global Home IVD Testing Market, by Region (APAC, EMEA, United States, Rest of World), 2019-2022
  • Competitive Analysis
    • Figure 6-5: Estimated Global Home IVD Testing Market, Vendor Market Share, by Top Five Market Vendors (Abbott, Dexcom, QuidelOrtho, Roche, Siemens Healthineers, Other), 2022